Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Recordati's 2013 sales performance.

Survival strategy

Pharmaceutical Corporation licensed its BPH drug to the medium-sized Italy-based company Recordati.

People, June, 2009

In 2005, he joined the Recordati Group to set up the UK subsidiary, which launched in March 2006. ... He worked tirelessly to make Recordati Pharmaceuticals a company that people wanted to work for and make a success.

Primary target

Type 1 or 2 diabetes mellitus . US. Lercanidipine/enalapril. Zanextra (Recordati)  . Hypertension. France. Levetiracetam. New Keppra XR (UCB). Partial-onset seizures . US. Milnacipran.

Recordati signs antihypertensive marketing agreement with Meda for Spain

Recordati signs a long-term agreement with Sweden-based Meda for the marketing and sale in Spain of its antihypertensive Zanipress. ... Recordati announced in late April 2007 that it had received marketing approval for Zanipress from the German medicines

Recordati acquires Orphan Europe

Recordati agrees to acquire Orphan Europe, a French pharmaceutical group specialising in rare diseases. ... Italian pharmaceutical company Recordati has agreed to acquire Orphan Europe (OE), a French company specialising in rare diseases.

[ Previous 5 results ] 1 2 3 4 5 6 7 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...
The era of digital wellbeing
Social media - friend or foe?...